Scilex Holding Company
NASDAQ:SCLXDrug Manufacturers - General
-$0.17 today
- Market cap
- $53.83M
- Beta
- 1.71
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.90
Volume 0.00M
Average 0.13M
SCLX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Scilex Holding CompanyNASDAQ: SCLX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $2.87M rose 186.0% year over year, ahead of the +61.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 80.7% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.
Context
- Depreciation & amortization amounted to 15.3% of revenue in FY2025, up 8.1 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +186.0% holds above the trailing-twelve-month pace of +61.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 4.62M USD
- Year-over-year change
- +14.3%
- 4-year CAGR
- +5.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.62M | +14.3% |
| FY2024 | 2024-12-31 | 4.05M | -2.4% |
| FY2023 | 2023-12-31 | 4.15M | +4.7% |
| FY2022 | 2022-12-31 | 3.96M | +4.8% |
| FY2021 | 2021-12-31 | 3.78M | — |
Depreciation & Amortization vs competitors
How SCLX compares with its peers on the latest reported figures
- SCLX's LTM Mar 2026 depreciation & amortization of $6.49M is the 4th largest of the 9 companies compared; the peer median is $3.94M.
- Its year-over-year change of +61.5% is the 4th highest of 8, against a peer median of +4.6%.
- Depreciation & amortization amounts to 19.2% of revenue for SCLX, versus a peer median of 19.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $429.44M | +48315.3% | -23.3% | 8364.7% | |
| LTM Mar 2026 | $8.78M | +4.6% | — | 47.7% | |
| LTM Mar 2026 | $7.38M | -44.0% | +24.3% | 6.0% | |
| LTM Mar 2026 | $6.49M | +61.5% | +5.3% | 19.2% | |
| LTM Mar 2026 | $4.89M | -22.2% | +22.5% | 32.5% | |
| LTM Mar 2026 | $2.99M | -3.9% | -18.4% | — | |
| LTM Mar 2026 | $880K | +391.6% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K | +130.4% | +136.6% | 0.4% |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding SCLX) | $3.94M | +4.6% | +22.5% | 19.2% | |
Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (88.42M) | (23.36M) | (114.33M) | (72.81M) | (358.73M) |
| Depreciation & Amortization | 3.78M | 3.96M | 4.15M | 4.05M | 4.62M |
| Deferred Income Tax | 12.76M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.82M | 5.28M | 14.6M | 15.69M | 15.49M |
| Change in Working Capital | 13.6M | 45.67M | 65.8M | 64.84M | 113.97M |
| Accounts Receivables | (1.14M) | (6.97M) | (13.36M) | (6.27M) | 13.84M |
| Inventory | (1.42M) | 1.18M | (2.84M) | 1.46M | 1.8M |
| Accounts Payables | (3.84M) | 2.81M | 19.88M | 7.42M | 13.12M |
| Other Working Capital | 20M | 48.65M | 62.12M | 62.23M | 85.21M |
| Other Non-Cash Items | 23.79M | (52.8M) | 9.08M | 7.58M | 228.47M |
| Operating Cash Flow | (28.66M) | (21.26M) | (20.71M) | 19.35M | 3.82M |
| Capital Expenditures | 0 | (2.07M) | (330K) | (600K) | (133K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (2.08M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (300K) | 0 | 4.22M |
| Investing Cash Flow | 0 | (2.07M) | (330K) | (2.68M) | 4.08M |
| Debt Repayment | (19.69M) | (31.25M) | 728K | (64.21M) | (2.81M) |
| Common Stock Issued | 0 | 96K | 35.46M | 44.64M | 27.88M |
| Common Stock Repurchased | 0 | 0 | (10M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 47.85M | 52.33M | (2.6M) | 1.44M | (30.53M) |
| Financing Cash Flow | 28.16M | 21.17M | 23.58M | (18.13M) | (5.46M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (756K) |
| Net Change in Cash | (501K) | (2.15M) | 2.55M | (1.46M) | 1.68M |
| Free Cash Flow | (28.66M) | (23.33M) | (21.04M) | 18.75M | 3.68M |
Scilex Holding Company
NASDAQ:SCLX
Intrinsic Alpha fair value
Locked
Current Price
$6.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.